Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CC001 is a botanical combination formula developed by the Amway (China) R&D Center, consisting of extracts from ginseng (*Panax ginseng*) and lily (*Lilium brownii*). The formulation is primarily investigated for its potential protective effects against respiratory damage and cardiovascular stress, particularly in the context of environmental pollutants such as PM2.5. Clinical evaluation has focused on the formula's ability to modulate inflammatory markers and improve antioxidant status in healthy adults exposed to air pollution. The product leverages the adaptogenic and anti-inflammatory properties of ginsenosides from ginseng alongside the traditional respiratory-supportive properties of lily polysaccharides.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on ginseng + lily extract.